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ABSTRACT
Introduction:  Biologic therapies have 
demonstrated efficacy and safety in several 
chronic systemic disorders. The authors 
indirectly compared response rates and costs per 
responder associated with biologic treatments 
for moderate-to-severe Crohn’s disease (CD), 
psoriasis (Ps), and/or rheumatoid arthritis (RA). 
Methods: A systematic literature search was 
performed to identify phase 3 randomized 
controlled trials of biologics for CD (adalimumab, 
infliximab), Ps (adalimumab, etanercept, 
infliximab, ustekinumab 45 mg, ustekinumab 
90 mg), or methotrexate-refractory RA (abatacept, 
adalimumab, certolizumab, etanercept, 
golimumab, infliximab, rituximab, tocilizumab). 
Food and Drug Administration-approved dosing 
schedules were evaluated. Published response 
rates were extracted, with response defined in 
CD, Ps, and RA as: ≥70-point reduction in CD 
Activity Index at 12 months; ≥75% improvement 
in Psoriasis Area and Severity Index at 3 months; 
and ≥50% improvement in American College of 
Rheumatology component scores at 6 months. 
Within each indication, mixed-treatment 
comparison meta-analyses were conducted to 
derive pooled estimates and 95% CIs of response 
rate difference versus placebo for each biologic, 
adjusting for cross-trial variation in control-arm 
response rates. Cost per responder was estimated 
for each biologic as projected per patient drug costs 
(2011 US$) divided by response rate difference. 
Results: Altogether, 23 publications were selected. 
In CD, 12-month cost per responder was estimated 
at $116,291 (95% CI $71,637, $208,348) for 
adalimumab and $125,169 (95% CI $60,532, 
$267,101) for infliximab. Among biologics approved 
in Ps, 3-month cost per responder was lowest for 
adalimumab ($9,756; 95% CI $8,668, $11,131), 
infliximab ($12,828; 95% CI $11,772, $13,922), and 
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Within each of these indications, the availability 
of highly efficacious biologic therapies has vastly 
improved the clinical management of patients 
with active disease despite the use of conventional 
therapies; the set of biologic drugs approved 
in CD, Ps, and/or RA includes monoclonal 
antibodies (adalimumab, certolizumab, 
golimumab, infliximab, rituximab, tocilizumab, 
ustekinumab) and recombinant fusion proteins 
(abatacept, etanercept) [1]. However, these are 
premium-priced products relative to traditional 
oral medications [8]. The added expenses of 
biologic drugs highlight the ongoing need for 
comparative effectiveness studies to optimize 
decisions about their use. To date, head-to-head 
randomized clinical trials comparing alternative 
biologic regimens are limited to trials of etanercept 
versus ustekinumab in Ps [9] and abatacept versus 
infliximab in RA [10]. In the absence of direct 
comparisons, an up-to-date indirect comparison of 
biologics via mixed treatment comparison (MTC) 
meta-analyses would be informative. 
Based on a comprehensive review of 
published clinical trials, the present study 
sought to compare biologic treatments using 
MTC meta-analyses of studies in CD, Ps, and 
RA. Specifically, the study compared cost per 
responder and cost per remitter across different 
treatments within each disorder, including: 
adalimumab and infliximab in CD; adalimumab, 
etanercept, infliximab, and ustekinumab in Ps; 
and abatacept, adalimumab, certolizumab, 
etanercept, golimumab, infliximab, rituximab, 
and tocilizumab in RA. Costs per responder and 
remitter provide measures of cost-effectiveness 
that have both clinical and economic 
significance to payers and physicians. 
For biologic drugs approved in two or 
more of the diseases, the results of the meta-
analyses were used to estimate overall costs per 
responder and remitter across indications. In 
order to contain biologic drug costs and promote 
ustekinumab 45 mg ($13,821; 95% CI $12,599, 
$15,167). In RA, biologics with the lowest 6-month 
cost per responder were adalimumab ($27,853; 95% 
CI $19,284, $40,270), etanercept ($29,140; 95% CI 
$14,170, $61,030), and tocilizumab ($31,363; 95% 
CI $14,713, $64,232). 
Conclusion: Meta-analyses of clinical trials found 
considerable variation in cost-effectiveness of 
biologic therapies for CD, Ps, and RA. These 
results may help determine biologic utilization 
in these chronic diseases.
Keywords: Biologic therapy; Cost-effectiveness; 
Cost per remitter; Cost per responder; Crohn’s 
disease; Psoriasis; Rheumatoid arthritis
INTRODUCTION
Since their introduction, targeted biologic 
therapies have demonstrated efficacy and safety 
in several chronic systemic disorders, with 
indications in gastroenterology, dermatology, 
and rheumatology [1]. In the US, multiple 
biologics are Food and Drug Administration-
approved for the treatment of Crohn’s disease 
(CD), plaque psoriasis (Ps), and rheumatoid 
arthritis (RA) in adult patients with moderate-
to-severe disease. CD, an inflammatory bowel 
disorder affecting approximately 0.2% of 
the population [2], is typically characterized 
by recurring exacerbations of abdominal 
pain, diarrhea, fever, and weight loss [3]. 
Ps is a common, debilitating autoimmune 
disorder that primarily affects the skin and 
joints, with a prevalence rate of 2.1% among 
US adults [4]. Patients with Ps experience 
physical pain and diminished quality of life 
due to erythematous plaques on the body 
surface [5, 6]. RA, a chronic inflammatory 
disorder, is prevalent in approximately 1% 
of US adults and can result in progressive 
joint damage and impaired mobility [7].
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to reflect general differences in the time 
horizon and design of phase 3 biologic drug 
trials between the three disease areas. Trials of 
adalimumab and infliximab in CD were included 
if they followed patients for a minimum of 
52 weeks, reported response and remission rates 
based on the Crohn’s Disease Activity Index 
(CDAI), and featured an induction-only placebo 
arm (i.e., patients were switched to placebo after 
receiving an induction regimen of the biologic), 
which is the usual comparison arm protocol 
that has been used in phase 3 trials of biologic 
drugs in CD. Studies of adalimumab, etanercept, 
infliximab, or ustekinumab for Ps were selected 
if they followed patients for at least 10 weeks, 
reported response rates based on the Psoriasis 
Area and Severity Index (PASI), and included 
either a placebo or another biologic in the 
trial. In RA, trials that evaluated methotrexate 
(MTX) combined with abatacept, adalimumab, 
certolizumab, etanercept, golimumab, infliximab, 
rituximab, or tocilizumab were included. Trials 
were also required to follow patients for a 
minimum of 24 weeks, report response rates based 
on the American College of Rheumatology (ACR) 
score, and feature a comparison arm consisting of 
MTX combined with either placebo or a different 
biologic treatment. Additionally, in order to 
minimize between-study heterogeneity and 
capture outcomes for the RA patient population 
most likely to be treated with biologic drugs in 
real-world clinical settings, the meta-analysis of 
RA trials was restricted to studies in which patients 
were required to have previously failed treatment 
with MTX; studies that enrolled patients who 
were MTX-naïve or who had previously failed 
biologic therapy were considered too dissimilar 
to combine with trials in the MTX-refractory 
population and were, therefore, excluded from 
the meta-analysis. 
All searches were conducted in the PubMed 
database; keywords included combinations 
optimal prescribing practices, payers need to 
consider the total expenditure on biologic drugs 
in combination with their effectiveness across 
all indications. Different indications typically 
encompass different dosing schedules; thus, 
the acquisition costs of biologic drugs can vary 
substantially by indication. The relative efficacy 
of biologic therapies is also highly dependent 
on the indication. However, because of the 
administrative burden of varying patient cost 
sharing and drug tier level by indication, it could 
be challenging for payers to manage biologic drug 
use when the drug has multiple indications [8]. 
In a 2005 poll of health plan directors on the 
expanded use of biologics, approximately 50% 
of participants responded that their organization 
would not be capable of appropriately managing a 
biologic therapy with multiple indications [8]. In 
cases where it is not feasible to manage coverage 
for a particular drug by indication, an analysis 
of blended cost-effectiveness across indications 
may provide a rational basis for the formulary 
management of drugs approved in more than one 
indication. Accordingly, the authors estimated 
blended costs per responder and remitter to 
compare adalimumab and infliximab across the 
CD, Ps, and RA indications, and to compare 
adalimumab, etanercept, and infliximab across 
the Ps and RA indications.
MATERIALS AND METHODS
Study Inclusion Criteria
A systematic literature review was performed 
to identify published randomized, controlled 
clinical trials of biologic therapies for the 
treatment of moderate-to-severe CD, Ps, or RA. 
The search was confined to phase 3 trials that 
evaluated a biologic treatment in comparison 
with either placebo or another biologic. Specific 
trial selection criteria varied by indication 
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of the disease plus any of the biologic drug 
names in that indication. Trials registered on 
ClinicalTrials.gov were also reviewed to check 
for additional studies.
Collection of Efficacy Data
Altogether, 23 publications met the selection 
criteria, including 2 in CD, 10 in Ps, and 11 in 
RA. For adalimumab and infliximab treatment in 
the CD indication, the clinical trials of Colombel 
et al. [11] and Hanauer et al. [12] were selected 
for inclusion. In both trials, all patients received 
induction biologic therapy and were then 
randomized to biologic therapy or placebo based 
on their initial response status. Initial clinical 
response was defined as a decrease in CDAI score 
of ≥70 points from baseline (CR-70), and was 
assessed at week 4 by Colombel et al. and week 
2 by Hanauer et al. Both publications reported 
subsequent efficacy outcomes among initial 
CR-70 responders only. For the present meta-
analysis, rates of CR-70 response and remission 
defined as CDAI <150 at approximately 1 year 
(i.e., week 54 or 56) were extracted for the 
initial responders population; the percentage of 
enrolled patients who achieved an initial CR-70 
response was also collected from either trial. 
The selected clinical trials of biologic drugs in 
Ps followed patients for a period of 10–16 weeks 
[9, 13–21]. Efficacy results in terms of PASI 75 
and PASI 90 response rates, defined respectively 
as improvements of ≥75% and ≥90% in PASI 
score from baseline, were extracted from each 
study. Because remission of Ps is not consistently 
defined in the literature, PASI 90 response was 
used as a proxy measure for remission in this 
indication. Whenever available, week 12 results 
were collected.
Rates of ACR 50 and ACR 70 response, defined 
respectively as improvements of ≥50% and ≥70% 
in the number of both swollen and tender 
joints and in at least three of five additional 
domain scores, were collected from clinical 
trials of biologic drugs in RA [10, 22–31]. Results 
were extracted for the study visit occurring at 
approximately 6 months (i.e., week 24–30). In RA, 
the percentage of patients achieving ACR 50 is 
the usual outcome used for response assessment; 
ACR 70 response was selected as a suitable 
proxy for remission owing to the inconsistent 
availability of other outcome measures for 
remission in the included trials.
Statistical Analysis
MTC Meta-Analysis
For each indication, meta-analyses were 
conducted to synthesize efficacy results from the 
included trials and derive pooled response and 
remission rates for each biologic regimen. The 
evidence synthesis method in the York/Woolacott 
cost-effectiveness model of biologic drugs for 
psoriasis was adapted for this MTC study [32]. 
Bayesian logistic regression was applied to 
analyze the dichotomous outcomes using Markov 
chain Monte Carlo with Gibbs sampling method 
by indication. An MTC meta-analysis approach 
was selected for its ability to synthesize summary-
level clinical evidence from multiple studies while 
adjusting for between-trial differences in placebo 
response rates [33–35]; in contrast to standard 
meta-analyses, this method also allowed for the 
combination of data from direct comparisons 
(i.e., trials comparing two different biologic drugs) 
with indirect evidence from placebo-controlled 
trials of biologics [36]. Using MTC, the relative 
efficacy of each biologic therapy was calculated 
in terms of incremental response/remission rate, 
defined as the difference in response/remission 
rates between the therapy and placebo. Based on 
the posterior distribution of the relative efficacy, 
the posterior mean was calculated as a point 
estimate of the relative efficacy, and 95% CIs were 
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approximated using the highest posterior density 
method. All Bayesian analyses were conducted 
using R/OpenBUGS software (R Foundation for 
Statistical Computing).
Number Needed to Treat
The number needed to treat (NNT) per additional 
responder/remitter associated with each biologic 
drug by indication was estimated using the 
point estimate of relative efficacy. NNT can be 
interpreted as the number of patients who need to 
be treated with a particular drug in order to achieve 
one additional positive outcome (i.e., response, 
remission) [37]. For each drug evaluated in Ps and 
RA, NNT per additional responder was calculated 
as the reciprocal of the incremental response 
rate versus placebo for that treatment. For drugs 
assessed in CD, a different formula for NNT was 
used owing to the design of the phase 3 clinical 
trials of adalimumab and infliximab for CD, in 
which results were reported for initial responders 
only. Specifically, patients with CD without an 
initial response to adalimumab or infliximab were 
assumed to discontinue therapy at week 4 and 
achieve neither response nor remission at 1 year. 
NNT per additional responder was accordingly 
estimated as: 1/([initial response rate]*[incremental 
response rate vs. placebo at 1 year among initial 
responders]). The corresponding 95% CI was 
approximated by the posterior distribution of the 
NNT based on the Markov chain Monte Carlo 
results. Similar calculations were performed for the 
NNT per additional remitter.
Measurement of Cost-Effectiveness
Costs per additional responder and remitter 
were estimated for each biologic drug as the 
estimated NNT multiplied by the projected drug 
cost per patient, and corresponding 95% CIs 
were estimated. In accordance with the length of 
the clinical trials included in the meta-analyses, 
drug acquisition and administration costs were 
calculated over a time horizon of 52 weeks in 
CD, 12 weeks in Ps, and 24 weeks in RA. In Ps 
and RA, costs were estimated by assuming full 
compliance to the indicated dosages within 
the specified time frame. In CD, per-patient 
cost was estimated with the assumption that 
initial responders had full compliance to the 
indicated dosages up to week 52, while initial 
nonresponders only received dosages before the 
end of week 4. 
For biologic drugs approved in multiple 
indications (adalimumab, etanercept, and 
infliximab), blended costs per additional 
responder and remitter were calculated as a 
weighted average of the estimated costs per 
additional responder and remitter across 
indications. To use a standardized time horizon 
across the three diseases, costs per additional 
responder/remitter within the Ps and RA 
indications were first recalculated using a 
52-week time frame, with the assumption that 
shorter-term response rates were maintained to 
year-end. Because etanercept is not approved in 
the CD indication, two separate comparisons 
were conducted: (i) blended costs per additional 
responder/remitter for adalimumab versus 
infliximab across CD, Ps, and RA; and (ii) blended 
costs per additional responder/remitter for 
adalimumab versus etanercept versus infliximab 
across Ps and RA. In either comparison, 
indication-specific cost per responder/remitter 
estimates were weighted in the blended average 
according to the total volume of biologic 
drug prescriptions written in the US for each 
indication. Prescription volume was used as an 
indicator of the size of the biologic market in 
each disease area, and was estimated based on 
Wolters Kluwer data in July 2010 (unpublished 
data), the most recent month of data available at 
the time of manuscript development.
For all calculations of costs per responder 
and remitter, US wholesale acquisition costs 
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with either biologic in CD, in which initial 
nonresponders were assumed to have failed 
treatment and discontinued biologic use by 
week 4. In CD, 12-month cost per responder was 
estimated at $116,291 (95% CI $71,637, $208,348) 
for adalimumab and $125,169 (95% CI $60,532, 
$267,101) for infliximab. Compared to infliximab, 
adalimumab was associated with reductions of 
$8,878 in cost per additional responder and $52,983 
in cost per additional remitter.
Meta-Analysis Results in Ps
In the MTC meta-analysis of biologic trials in 
Ps, incremental PASI 75 response rates relative 
to placebo were highest for infliximab (74.9%) 
and ustekinumab 90 mg (67.9%) (Table 4). 
Adalimumab (64.4%) and ustekinumab 45 mg 
(62.7%) had comparable incremental response 
rates, while etanercept showed the lowest 
response probability versus placebo (47.0%). 
The relative efficacy of the comparator drugs in 
terms of remission, assessed based on PASI 90 
response, showed a similar pattern.
Over the 12-week time horizon, adalimumab 
was associated with the lowest cost per 
additional responder ($9,756; 95% CI $8,668, 
$11,131) among the biologics in Ps, followed by 
infliximab ($12,828; 95% CI $11,772, $13,922), 
ustekinumab 45 mg ($13,821; 95% CI $12,599, 
$15,167), etanercept ($21,770; 95% CI $19,231, 
$24,644), and ustekinumab 90 mg ($25,327; 95% 
CI $23,372, $27,332) (Table 5). Results were similar 
with respect to costs per additional remitter.
Meta-Analysis Results in RA
Based on the meta-analysis of trials among 
patients with MTX-refractory RA, the biologics 
with the highest incremental ACR 50 
response probabilities relative to placebo were 
adalimumab (36.1%), etanercept (35.1%), and 
as of January 2011 were used to determine 
drug acquisition costs (ReadyPrice®, Thomson 
Micromedex, Greenwood Village, Colorado, 
USA). Recommended dosing schedules 
based on US labels were assumed for each 
drug (Table 1). Per-infusion drug cost for 
abatacept, infliximab, and tocilizumab were 
calculated based on an average weight of 
70 kg in CD [11] and RA [26], and 90 kg 
in Ps [14]. Administration cost per infusion was 
obtained from Medicare Current Procedural 
Terminology (CPT) payment information for 
2011 (CPT codes 96413 and 96415 for abatacept, 
infliximab, rituximab, and tocilizumab; CPT 
code 96401 for certolizumab and ustekinumab). 
Drug acquisition and administration costs were 
prorated in order to obtain total costs over the 
specified time horizon within each indication.
RESULTS
Meta-Analysis Results in CD
In the included phase 3 clinical trials of both 
adalimumab and infliximab, the proportion 
of patients who achieved an initial response to 
biologic induction therapy constituted 58% of the 
overall trial population. The MTC meta-analysis 
performed in the CD indication analyzed response 
and remission rates to adalimumab and infliximab 
within the initial responder population from either 
trial. Results from the meta-analysis indicated that, 
among initial responders, the incremental CR-70 
response rate (i.e., the difference in response rates 
between treatment vs. induction-only placebo) was 
24.7% (95% CI 12.6%, 37.5%) for adalimumab and 
20.8% (95% CI 7.7%, 34.9%) for infliximab (Table 2). 
Adalimumab (23.6%; 95% CI 10.4%, 38.1%) also 
had a higher incremental remission rate compared 
to infliximab (14.9%; 95% CI 2.6%, 27.2%) (Table 2).
Table 3 presents the NNTs and 52-week costs 
per additional responder and remitter associated 
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and cost per remitter associated with different 
biologic therapies approved for the treatment 
of CD, Ps, and RA in the US. In addition to 
comparing biologic drugs for each indication, 
the study estimated cross-indication 1-year costs 
per responder/remitter for biologics approved 
in at least two of the three indications studied 
(i.e., adalimumab, etanercept, and infliximab). 
Consistent with a previous cost-effectiveness study 
of biologics for moderately-to-severely active CD 
in the US [38], adalimumab was associated with 
lower 1-year costs per responder and remitter 
compared to infliximab within the CD indication. 
Adalimumab also had the lowest 12-week costs 
per responder and remitter of the biologics 
assessed in Ps, followed by infliximab 5 mg/kg 
and ustekinumab 45 mg; these results echoed 
findings from a previous cost-effectiveness study 
conducted by Schmitt-Rau et al. [39] in moderate-
to-severe Ps. Among the biologics evaluated in 
RA, adalimumab had the lowest 24-week cost per 
responder, followed by etanercept, tocilizumab, 
and certolizumab. RA drugs with the lowest cost 
per remitter were adalimumab and tocilizumab. 
Consistent with indication-specific results, 
adalimumab demonstrated lower 1-year costs 
per additional responder and remitter versus 
etanercept and infliximab in Ps and RA, and versus 
infliximab in CD, Ps, and RA.
Overall, cost-effectiveness varied substantially 
across biologics, particularly for Ps and RA. In 
Ps, 12-week costs per responder and remitter 
were more than twice as high for etanercept 
and ustekinumab 90 mg than adalimumab. 
In RA, rituximab, abatacept, and infliximab 
had notably higher costs per responder and 
remitter compared to other drugs evaluated. 
The present analysis considers only biologic 
drug acquisition and infusion costs and does not 
capture additional medical expenses associated 
with treatment failure, such as hospitalization 
costs. Nonetheless, the wide variation in costs 
certolizumab (33.3%) (Table 6). Incremental 
remission probabilities based on ACR 70 were 
highest for adalimumab (21.1%), certolizumab 
(19.8%), and etanercept (16.4%).
Cost per additional responder over 24 weeks was 
lowest for adalimumab ($27,853; 95% CI $19,284, 
$40,270), followed by etanercept ($29,140; 95% 
CI $14,170, $61,030), tocilizumab ($31,363; 95% 
CI $14,713, $64,232), and certolizumab ($34,979; 
95% CI $23,636, $51,166) (Table 7); higher costs 
per responder were estimated for rituximab, 
abatacept, infliximab, and golimumab. The lowest 
costs per additional remission were estimated for 
adalimumab ($47,533; 95% CI $23,939, $86,730) 
and tocilizumab ($48,320; 95% CI $15,766, 
$135,922).
Cross-Indication Results
In the calculation of cross-indication 1-year costs 
per additional responder/remitter, the indication-
specific results in CD, Ps, and RA were weighted 
in a ratio of 1:1.02:5.07 according to the relative 
volume of prescriptions written for biologics in 
each disease area. The weighted average 1-year 
cost per additional responder across the Ps and RA 
indications was $56,219 (95% CI $40,592, $78,426) 
for adalimumab, $62,283 (95% CI $34,815, 
$119,476) for etanercept, and $82,683 (95% CI 
$46,082, $146,609) for infliximab (Table 8). Blended 
1-year cost per additional remitter in Ps and RA was 
lower for adalimumab by $38,445 compared to 
etanercept and by $40,101 compared to infliximab. 
Across all three indications, adalimumab was 
associated with $23,984 and $41,919 lower 1-year 
costs per additional responder and remitter relative 
to infliximab, respectively (Table 9). 
DISCUSSION
This study used MTC meta-analyses of published 
clinical trials to evaluate the cost per responder 
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time horizons. Thus, one limitation of this study 
is the paucity of long-term efficacy data available 
for the evaluation of costs per responder/remitter 
within the Ps and RA indications. The clinical 
efficacies of biologics are well-reported during 
the first 3 months of treatment in patients with 
moderate-to-severe Ps [9, 13–21], and during the 
first 6 months of therapy in patients with moderate-
to-severe, methotrexate-refractory RA [10, 22–31]; 
however, few randomized, double-blinded, placebo-
controlled trials have documented the benefits of 
biologics over longer time frames in these patient 
populations. The analysis of 1-year cross-indication 
costs per responder/remitter, therefore, assumed 
that short-term response rates in Ps and RA were 
maintained to year-end, similar to the approach 
used in previous cost-effectiveness analyses of 
biologics [32, 35].
In this study, the efficacy of different biologic 
drugs was compared using a MTC meta-analysis of 
clinical trials. While clinical trials provide unbiased 
comparisons of clinical efficacy in a controlled 
environment, the strict treatment protocols 
and eligibility criteria used in such studies may 
not be representative of actual clinical practice. 
For example, differing levels of compliance and 
persistence to biologic therapies may be a more 
per responder and remitter across biologics 
demonstrates the potential usefulness of 
comparative effectiveness research in informing 
treatment decisions and formulary placement in 
these three disease areas.
To the authors’ knowledge, the present 
study is the first to evaluate the blended cost-
effectiveness of biologics across indications. 
As exemplified by cost-effectiveness results for 
adalimumab, etanercept, and infliximab across 
their indications, a biologic therapy approved 
in multiple indications is likely to be associated 
with varying clinical efficacy, dosing regimens, 
and acquisition costs depending on the disease. 
Thus, in the context of expanded indications for 
biologics, payers must identify and implement 
feasible strategies for promoting appropriate 
utilization of biologics within each disease 
area; such strategies may aim to stratify drug 
coverage by patient population. In the meantime, 
information on the cross-indication cost-
effectiveness of biologics may assist formulary 
decision-making by facilitating the comparison 
of therapies approved for the same set of diseases.
Because CD, Ps, and RA are chronic disorders, 
the cost-effectiveness of biologic therapies for these 
indications should ideally be assessed over long 
Table 9  Cross-indication costs per responder and remitter in Crohn’s disease, psoriasis, and rheumatoid arthritis
Indication
1-year cost per additional responder (95% CI)   1-year cost per additional remitter (95% CI)
Adalimumab Infliximab   Adalimumab Infliximab
































a In the pooled estimates of cost per responder and remitter across indications, each indication was weighted according to 
the number of biologic prescriptions written for that disease area in the US, based on Wolters Kluwer data for July 2010 
(unpublished data)
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